Table 4C.
Influence of complicated allergy.
| tIgE(KU/L) | CSMS without omalizumab | CSMS with omalizumab | CSMS improvement | Recovery rate1 | |
|---|---|---|---|---|---|
| Mould allergy | |||||
| Without mould allergy (n=31) | 162.0[104.1,448.0] | 2.67[1.00,3.00] | 1.00[0.17,2.00] | 2.54 ± 1.27 | 7(22.6%) |
| Complicated with mould allergy (n=7) | 153.0[119.0,183.0] | 2.67[2.00,2.83] | 0.83[0.33,1.83] | 2.69 ± 1.22 | 1(14.3%) |
| P-value | 0.907 | 0.825 | 0.854 | 0.789 | 1.000 |
| Dust mite allergy | |||||
| Without dust mite allergy (n=34) | 158.0[99.1,398.5] | 2.67[1.00,3.00] | 0.92[0.13,1.87] | 2.69 ± 1.44 | 8(23.5%) |
| Complicated with dust mite allergy (n=5) | 197.0[136.5,1065.5] | 0.92[0.83,2.50] | 0.17[0.00,0.50] | 3.67 ± 1.10 | 2(40.0%) |
| P-value | 0.218 | 0.581 | 0.334 | 0.255 | 0.587 |
| Number of autumn pollen allergen | |||||
| Single allergen (n=14) | 115.5[58.4,274.5] | 3.00[2.83,4.21] | 0.33[0.00,2.00] | 2.63 ± 0.29 | 5(35.7%) |
| Multiple allergen (n=50) | 162.0[104.0,435.0] | 4.50[3.00,5.00] | 0.83[0.00,1.83] | 2.79 ± 0.22 | 14(28.0%) |
| P-value | 0.138 | 0.095 | 0.323 | 0.676 | 1.000 |